AbbVie (NYSE:ABBV – Get Free Report) and Neuphoria Therapeutics (NASDAQ:NEUP – Get Free Report) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, profitability, risk, institutional ownership, dividends, valuation and earnings.
Profitability
This table compares AbbVie and Neuphoria Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| AbbVie | 15.67% | -450.55% | 16.50% |
| Neuphoria Therapeutics | N/A | -38.31% | -28.92% |
Insider & Institutional Ownership
70.2% of AbbVie shares are owned by institutional investors. Comparatively, 15.9% of Neuphoria Therapeutics shares are owned by institutional investors. 0.1% of AbbVie shares are owned by insiders. Comparatively, 1.5% of Neuphoria Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Valuation & Earnings
This table compares AbbVie and Neuphoria Therapeutics”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| AbbVie | $61.16 billion | 8.62 | $4.23 billion | $5.81 | 51.33 |
| Neuphoria Therapeutics | $1.17 million | 11.66 | -$13.45 million | ($6.22) | -0.41 |
AbbVie has higher revenue and earnings than Neuphoria Therapeutics. Neuphoria Therapeutics is trading at a lower price-to-earnings ratio than AbbVie, indicating that it is currently the more affordable of the two stocks.
Analyst Recommendations
This is a breakdown of current ratings and price targets for AbbVie and Neuphoria Therapeutics, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| AbbVie | 0 | 6 | 22 | 1 | 2.83 |
| Neuphoria Therapeutics | 1 | 2 | 0 | 0 | 1.67 |
AbbVie presently has a consensus target price of $297.85, suggesting a potential downside of 0.12%. Neuphoria Therapeutics has a consensus target price of $7.00, suggesting a potential upside of 176.68%. Given Neuphoria Therapeutics’ higher probable upside, analysts clearly believe Neuphoria Therapeutics is more favorable than AbbVie.
Risk & Volatility
AbbVie has a beta of 0.2, indicating that its share price is 80% less volatile than the S&P 500. Comparatively, Neuphoria Therapeutics has a beta of 0.77, indicating that its share price is 23% less volatile than the S&P 500.
Summary
AbbVie beats Neuphoria Therapeutics on 10 of the 15 factors compared between the two stocks.
About AbbVie
AbbVie is a biopharmaceutical company that discovers, develops and markets medicines for a range of serious health conditions. Its research and product portfolio spans immunology, oncology, neuroscience and other therapeutic areas. Key products include the immunology medicines Skyrizi and Rinvoq, cancer treatments such as Imbruvica and Venclexta, and neuroscience therapies including Botox and Vraylar. Through its Allergan acquisition, AbbVie also offers aesthetics products such as Botox Cosmetic and Juvéderm.
About Neuphoria Therapeutics
Neuphoria Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing investigational treatments for neurological and psychiatric conditions. The company’s work centers on advancing drug candidates intended to address needs in brain health. Its products remain in development rather than being established, marketed therapies. Publicly available information about Neuphoria’s specific development programs, operating geographies and leadership is limited, so no additional details are included here.
Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.
